SMS Pharmaceuticals receives non-exclusive licence to manufacture and supply Molnupiravir through MPP
The step has been taken to increase broad access of COVID-19 treatment in 105 Low- and Middle- Income Countries (LMICs)
SMS Pharmaceuticals has received a non-exclusive license through the Medicines Patent Pool (MPP) to manufacture Molnupiravir to increase broad access of COVID-19 treatment in 105 Low- and Middle- Income Countries (LMICs), a statement from SMS Pharma said.
It also noted that MSD has entered into an agreement to license this pill for wider distribution with the patent group. Under the terms of the agreement, MPP, through the licence granted by MSD, will be permitted to further licence non-exclusive sublicences to manufacturers and diversify the manufacturing base for the supply of Molnupiravir to countries covered by the MPP licence, subject to local regulatory authorisation.
- Advertisement -